• Mashup Score: 0
    Please wait whilst we redirect you - 1 year(s) ago

    About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2023 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.ScienceDirect® is a registered trademark…

    Source: www.sciencedirect.com
    Categories: Latest Headlines, Oncologists1
    Tweet Tweets with this article
    • Profile photo of LoiSher
      LoiSher

      hi everyone, for those who have been asking for the PDF, the article is free online here for 50days #bcsm #breastcancer #Tils #Tcells #Immunotherapy https://t.co/J2T7wLul1O

  • Mashup Score: 0
    First-Line Treatment Paradigm of NSCLC and the Advent of Immunotherapy - 1 year(s) ago

    Joshua Sabari, MD, a thoracic medical oncologist at NYU Langone Health Perlmutter Cancer Center in New York, NY reviews clinical trial data and explains the rationale of using tumor-infiltrating lymphocytes (TILs) in non-small cell lung cancer (NSCLC) treatment.

    Source: Targeted Oncology
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of TargetedOnc
      TargetedOnc

      Joshua Sabari, MD, a thoracic medical oncologist at NYU Langone Health Perlmutter Cancer Center in New York, NY reviews clinical trial data and explains the rationale of using #TILs in #NSCLC treatment. #lcsm | @JSabari @nyulangone @Perlmutter_CC https://t.co/hMhkJF7awL

  • Mashup Score: 3
    Hematopoietic Cell Transplantation and Cell therapy weekly newsletter - Issue #10 - 2 year(s) ago

    OUT THIS WEEK!!!Tisacel FDA approved for R/R follicular lymphomaNeoantigen for TCR cell therapy in pancreatic cancerTILS for breast cancerAza helps anti-CD70 CARTs for AMLSequential IDA-FLAG and melphalan for R/R AML, no so brilliant long-term resultsMMF effect in PTCy GVHD prophylaxis in MRD alloHCTNIH atypical cGVHD features 2020

    Source: www.getrevue.co
    Categories: Hematologists1, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of albertomussetti
      albertomussetti

      Read my latest: “Hematopoietic Cell Transplantation and Cell therapy weekly newsletter - Issue #10” https://t.co/ZZ97Rl7OOl @NEJM @ASTCT_journal @theEBMT @Cancer_Cell #CART #alloHCT #TCR #TILS #neoantigens

  • Mashup Score: 2
    Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer - npj Breast Cancer - 2 year(s) ago

    The importance of integrating biomarkers into the TNM staging has been emphasized in the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging system. In a pooled analysis of 2148 TNBC-patients in the adjuvant setting, TILs are found to strongly up and downstage traditional pathological-staging in the Pathological and Clinical Prognostic Stage Groups from the AJJC 8th edition…

    Source: Nature
    Categories: Latest Headlines, Oncologists1
    Tweet Tweets with this article
    • Profile photo of LoiSher
      LoiSher

      Integrating biomarkers into the TNM staging is important in the 8th Ed of the American Joint Committee on Cancer (AJCC) Staging. Here #TILs can strongly up or downstage eTNBC. #openaccess #tnbc #breastcancer @BCRFcure @NBCFAus @OncoAlert @TILsWorkGroup https://t.co/MVlq9hQxU2

  • Mashup Score: 0
    Prior therapy may reduce efficacy of tumor-infiltrating lymphocytes for advanced melanoma - 2 year(s) ago

    Prior treatment with newer-generation therapies appeared associated with significantly lower objective response rates among patients who received tumor-infiltrating lymphocytes for metastatic melanoma, according to study findings.Early clinical trials of adoptive tumor-infiltrating lymphocytes (TILs) for metastatic melanoma showed consistent objective response rates of approximately 50%,

    Source: www.healio.com
    Categories: General Medicine News, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of GoHealio
      GoHealio

      🎙Stephanie L Goff, MD, FACS discusses research from @NIH & @theNCI showing how prior use of newer-gen therapies may reduce efficacy of tumor-infiltrating lymphocytes for advanced #melanoma https://t.co/kVdBLqj628 #TILs #CellTherapyNext @slgoff_SB

  • Mashup Score: 0
    Prior therapy may reduce efficacy of tumor-infiltrating lymphocytes for advanced melanoma - 2 year(s) ago

    Prior treatment with newer-generation therapies appeared associated with significantly lower objective response rates among patients who received tumor-infiltrating lymphocytes for metastatic melanoma, according to study findings.Early clinical trials of adoptive tumor-infiltrating lymphocytes (TILs) for metastatic melanoma showed consistent objective response rates of approximately 50%,

    Source: www.healio.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of HemOncToday
      HemOncToday

      🎙Stephanie L Goff, MD, FACS discusses research from @NIH & @theNCI showing how prior use of newer-gen therapies may reduce efficacy of tumor-infiltrating lymphocytes for advanced #melanoma https://t.co/n94FsLrQln #TILs #CellTherapyNext @slgoff_SB

  • Mashup Score: 0
    Tumor-infiltrating lymphocyte cell therapy ‘potentially viable’ option for advanced NSCLC - 2 year(s) ago

    Nearly a quarter of patients with heavily pretreated non-small cell lung cancer achieved an objective response to an infusion of LN-145, according to study results presented at Society for the Immunotherapy of Cancer Annual Meeting.Early results from the phase 2 trial of the investigational tumor-infiltrating lymphocyte (TIL) cell therapy also showed a disease control rate of 65%.

    Source: www.healio.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of HemOncToday
      HemOncToday

      NEWS from #SITC21 - Tumor-infiltrating lymphocyte cell therapy ‘potentially viable’ option for advanced non-small cell lung cancer https://t.co/WK3TZuulSJ #TILs #LCSM @IovanceBio @sloan_kettering #CellTherapyNext

Load More